Trials / Completed
CompletedNCT02449603
Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes
Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes : a Randomised Open Parallel-controlled Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Xijing Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-centre, open-label, randomized, parallel trial to compare the effect of Exenatide versus Biphasic insulin Aspart 30 on glucose variability and inflammatory markers in type 2 diabetes mellitus (T2DM) patients inadequately controlled with metformin monotherapy.
Detailed description
Studies have showed that fluctuations of glucose seem to have more deleterious effects than sustained hyperglycaemia in the development of diabetic complications. The present randomized controlled trial was designed with primary aim to evaluate glycaemic fluctuation in the comparison between twice-daily Exenatide and other treatment paradigm (e.g. insulin Aspart 30).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Exenatide | |
| DRUG | Biphasic insulin Aspart 30 |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2018-04-01
- Completion
- 2018-04-01
- First posted
- 2015-05-20
- Last updated
- 2018-11-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02449603. Inclusion in this directory is not an endorsement.